

## Prevention & Treatment of Hepatitis and Chronic Liver Disease

**Pasadena, CA October 5, 2024**

<b>Conference Location</b>	<b>Hotel Dena</b> 303 Cordova Street Pasadena, CA 91101	<b>Phone: (626) 469-8100</b> <a href="https://www.hoteldena.com">https://www.hoteldena.com</a>
----------------------------	---	---

<b>Parking at the Conference</b>	A discounted Self-Parking of \$15,00 per day has been arranged for all participants. Please bring your parking ticket to the seminar registration desk to receive this rate.
----------------------------------	--

<b>Driving Directions</b>	<p><b>From US-101 S/(Ventura Fwy) OR US 5 (Golden State Fwy) and CA-134 E (Pasadena Fwy):</b></p> <ul style="list-style-type: none"> <li>• Continue on CA-134 E, follow signs for Burbank/Pasadena</li> <li>• Take exit 25C for Fair Oaks Ave toward Marengo Ave</li> <li>• Merge onto Corson Street</li> <li>• Turn Left at Marengo Ave</li> <li>• The hotel will be on the left side just before Cordova St</li> </ul>
---------------------------	--

<b>Seminar Agenda and Syllabus Information</b>	Registration begins at <b>7:30 a.m.</b> outside the Magnolia Room on the lower level.
--	---

The Hepatitis and Chronic Liver Disease seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet or personal computer. Instructions to download the *App* will be provided. Wi-Fi will be available without charge.

<b>Pre-Program Activities</b>	<p><b>Pre-Lecture 1 – Viral Hepatitis</b> –A summary for discovery and natural history of HCV 60 min</p> <p><b>Pre-Lecture 2 - End Stage Liver Disease:</b> An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min</p>
<b>7:30 am</b>	<i>Registration and View Exhibits</i>
<b>8:00 am</b>	<b>Opening Comments and Pre-Test</b>
<b>8:20 am</b>	<p><b>Advances in the Screening and Treatment of HCV</b></p> <ul style="list-style-type: none"> <li>• Updates on diagnostic approaches</li> <li>• Caring for At-risk populations – homeless, PWID, the incarcerated</li> <li>• Novel FDA Approved Direct Acting Anti-virals</li> <li>• Clinical Cases and Discussion</li> </ul>
<b>9:10 am</b>	<p><b>Hepatitis B: Epidemiology, History, Testing and Treatment</b></p> <ul style="list-style-type: none"> <li>• The epidemiology of the Hepatitis B infection</li> <li>• Efficacies and opportunities in HBV testing and vaccination</li> <li>• The efficacy of HBV Vaccination and Anti-viral therapies of HBV</li> <li>• HBV Re-activation and the Latest studies from EASL and AASLD</li> </ul>
<b>9:40 am</b>	<p><b>Delta Hepatitis and Hepatitis E Update</b></p> <ul style="list-style-type: none"> <li>• Global and US perspective on the growth of Delta Hepatitis</li> <li>• Lonafarnib and Bulevirtide of HDV: Benefits and potential hazards</li> <li>• Testing and surveillance approaches</li> <li>• Real world outcome studies on HDV and HEV</li> </ul>
<b>10:15 am</b>	<i>Break and View exhibits</i>
<b>10:30 am</b>	<p><b>End Stage Liver Disease: Recap and Clinical Cases</b></p> <ul style="list-style-type: none"> <li>• A review of Pre-course lecture on end-stage liver disease</li> <li>• Complications of cirrhosis</li> </ul>

	<ul style="list-style-type: none"> <li>• Liver transplant in the era of DAA's</li> <li>• Clinical cases to illustrate HE, HRS and/or Thrombocytopenia</li> </ul>
11:05 am	<b>Hepatocellular Carcinoma(HCC) - Screening and Disease Progression</b> <ul style="list-style-type: none"> <li>• Screening diagnostic serum assays and imaging tests</li> <li>• Treatment and management options: Ablation, TACE and Surgery</li> <li>• New studies showing cost effectiveness of surveillance post SVR</li> <li>• PRIUS Study (MRI vs US) Abbreviated MRI</li> <li>• 2023 AASLD screening guidance for liver cancer and comments on biopsy for HCC</li> </ul>
11:40 am	<b>Hepatocellular Carcinoma: A case-based approach to New Systemic Treatment Options</b> <ul style="list-style-type: none"> <li>• Promising 1<sup>st</sup> and 2<sup>nd</sup> line therapies for liver cancer</li> <li>• New data on the benefit of downstaging</li> <li>• C chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC</li> <li>• Checkpoint inhibitors and VEGE inhibitors</li> </ul>
12:20 pm	<b>Luncheon and Product Information Session</b>
12:55 pm	<b>Dessert and View Exhibits</b>
1:05 pm	<b>Cholestatic Liver Disease: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis</b> <ul style="list-style-type: none"> <li>• Epidemiology of PSC and Ursodiol and Antibiotic Treatments</li> <li>• Causes and Markers of PBC</li> <li>• Coping with the clinical features of PBC</li> <li>• Ursodeoxycholic Acid (UDCA) and Obeticholic Acid</li> <li>• Highlights of the ELATIVE study on elafibranor and the RESPONSE study on seladelpar</li> </ul>
1:55 pm	<b>Alcohol Associated Liver Disease</b> <ul style="list-style-type: none"> <li>• The growing prevalence of alcohol over-consumption and its impact on liver health</li> <li>• Alcohol consumption and malnutrition</li> <li>• Warning signs and intervention in alcohol-associated hepatitis</li> <li>• Promising therapeutic agents for AAH</li> </ul>
2:30 pm	<ul style="list-style-type: none"> <li>• <b>Break &amp; View Exhibits</b></li> </ul>
2:45 pm	<b>Steatotic Liver Disease: The new healthcare epidemic</b> <ul style="list-style-type: none"> <li>• New naming conventions for fatty liver disease: MASLD and MASH– what and why?</li> <li>• Epidemiology, Demographics and Diagnosis</li> <li>• Scoring, Staging and Management of Metabolic Liver Disease</li> <li>• The ‘unhealthy’ rise in MASLD in the US population and What can be done Treatment options for thrombocytopenia; including alternatives to platelet transfusion.</li> </ul>
3:20 pm	<b>MASH Treatments in Practice and in Development</b> <ul style="list-style-type: none"> <li>• Current therapies for NASH including Updates from AASLD and EASL</li> <li>• Lifestyle changes as a therapy</li> <li>• Drugs in clinical development for NASH – Semaglutide and Resmitemon</li> <li>• MASH Diagnosis and Treatment case</li> </ul>
4:00 pm	<b>Closing Comments, Post-test and Wrap-Up</b> Program adjourns at 4:15 pm
Post-program activities	<b>Lecture 3 - Fluid Management, Ascites and Hepatorenal Syndrome</b> 30 minutes <b>Lecture 4 - Overcoming barriers to liver health in special populations</b> - 30 minutes. <b>Lecture 5 – AASLD Update – Highlights of the 2023 Liver Meeting</b> – 30 minutes

### Attendance Policies

#### Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

#### Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

---

**Guest Attendance**

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues, and others.) are not permitted in the seminar areas.

**Conference Modification or Cancellation**

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course's schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

---

**CME  
Information**

**Physicians (MD/DO)** - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)**<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses** - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-24-1383. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

**Nurse Practitioners and Physician Assistants** - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)<sup>™</sup> organizations accredited by ACCME.

---

**SAMMY SAAB, MD, MPH**

Sammy Saab is a Professor in the Departments of Internal Medicine and Surgery at the David Geffen School of Medicine. He is also Head of Outcomes Research in Hepatology at the Pflieger Liver Institute.

Dr. Saab received his BS, MD, and MPH from UCLA. He completed his residency in internal medicine at University of California at San Diego Medical Center and a fellowship in gastroenterology/hepatology at UCLA Center for Health Sciences. Dr. Saab is board certified in internal medicine, gastroenterology, and transplant hepatology. He has received honorary fellowships from the American Gastroenterology Association (AGAF), American College of Gastroenterology (FACG) and the American Association for the Study of Liver Diseases (FAASLD).

**SARO KHEMENCHIAN, MD**

Dr. Saro Khemichian is a board-certified transplant hepatologist who received his medical degree from Keck School of Medicine of USC. He then went on to complete his residency in Internal Medicine followed by Gastroenterology fellowship at LAC+USC Medical Center in Los Angeles.

Dr. Khemichian then completed an extra year of training for Transplant Hepatology at Keck Medical Center of USC. Dr. Khemichian's clinical interests include gastroenterology, hepatitis B, hepatitis C, chronic liver disease and liver transplantation. His research interests include complications of chronic liver disease, liver transplant, and treatment of hepatitis C infection.

**LUCY MATHEW, ACNP-BC**

Lucy Mathew is a nationally certified Nurse Practitioner with a Master's degree in the specialty of Acute Care Nurse Practitioner. She graduated from UCLA in 1998. For the past fourteen years, she has been working with patients with a variety of liver diseases, specializing in viral hepatitis and cirrhosis. She is an expert in this field and has given many lectures to peers. Lucy is also involved in many clinical trials at Cedars Sinai Medical Center.

She has organized nursing symposiums and has been a speaker in many local and national level educational meetings.

**Your  
Seminar  
Faculty**